StonvexLoading…
StonvexStonvexStonvexCore line items from NIVF's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $23.71M | $371.67K | $446.00K | $506.34K |
Operating Income | $-10.73M | $-1.16M | $42.24K | $398.70K |
Net Income | $9.88M | $-524.64K | $130.19K | $458.67K |
EPS (Diluted) | $3.04 | $-4408.76 | $13019.30 | $4.72 |
Total Assets | $32.72M | $3.58M | $4.49M | $2.90M |
Total Liabilities | $6.74M | $5.06M | $1.24M | $2.80M |
Cash & Equivalents | $758.62K | $457.74K | $54.10K | $27.56K |
Free Cash Flow OCF − CapEx | $-11.06M | $-8.32M | $-1.84M | $1.62M |
Shares Outstanding | 240.62K | 380 | 507.47K | 601.83K |